The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report

BackgroundDocetaxel combined with prednisone plus androgen deprivation therapy (ADT) is the preferred treatment option for metastatic hormone-sensitive prostate cancer (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC). With the development of next-generation hormonal agents (NHAs) a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-09-01
coleção:	Frontiers in Oncology
Assuntos:	prostate cancer (PCa) metastatic castration-resistant prostate cancer (mCRPC) second docetaxel rechallenge (DR) later-line treatment case report
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1185530/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!